Drug tested for deadly Skin-Shedding disease
NCT ID NCT06474078
Summary
This small, completed pilot study tested whether the drug tofacitinib could help patients with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). These are rare, life-threatening conditions where the skin and mucous membranes blister and peel off. All 20 participants received the drug, and researchers measured how long it took for their skin to heal completely, how long they stayed in the hospital, and whether there were any safety issues.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEVENS - JOHNSON SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chang Gung Memorial Hospital
Taoyuan District, 333, Taiwan
Conditions
Explore the condition pages connected to this study.